Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -351.86% is 505% below its 5-year average of -58.18%, near the low end of its 5-year range (-351.86%–-25.17%).
As of the fiscal period ended Tuesday, June 30, 2026. 52.43% below its 12-month average of -230.83%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -351.86%.
RETURN ON EQUITY (ROE)
-351.86%
RETURN ON EQUITY (ROE) AVG TTM
-230.83%
RETURN ON EQUITY (ROE) AVG 3Y
-130.66%
RETURN ON EQUITY (ROE) AVG 5Y
-58.18%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-52.43%
CURRENT VS 3Y AVG
-169.29%
CURRENT VS 5Y AVG
-504.79%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-737.57%
vs the sector median at left
NextCure, Inc.
Market Cap
$20.16M
Return on Equity (ROE)
-351.86%
TTM Avg
-230.83%
3Y Avg
-130.66%
5Y Avg
-58.18%
Market Cap
$20.95M
Return on Equity (ROE)
-313.46%
TTM Avg
-251.20%
3Y Avg
-178.74%
5Y Avg
-144.62%
Market Cap
$19.14M
Return on Equity (ROE)
-2067.81%
TTM Avg
-13234.78%
3Y Avg
-6645.16%
5Y Avg
-6645.16%
Market Cap
$18.80M
Return on Equity (ROE)
-136.36%
TTM Avg
-41.80%
3Y Avg
-1184.66%
5Y Avg
-795.29%
Market Cap
$18.81M
Return on Equity (ROE)
-75.34%
TTM Avg
-0.67%
3Y Avg
-77.39%
5Y Avg
-61.36%
Market Cap
$21.93M
Return on Equity (ROE)
-260.37%
TTM Avg
-164.08%
3Y Avg
-188.26%
5Y Avg
-64.22%
Market Cap
$22.22M
Return on Equity (ROE)
-40.40%
TTM Avg
-55.95%
3Y Avg
-53.10%
5Y Avg
-83.38%
Market Cap
$17.99M
Return on Equity (ROE)
N/A
TTM Avg
-3014.83%
3Y Avg
-1589.49%
5Y Avg
-1032.64%
Market Cap
$22.36M
Return on Equity (ROE)
-421.06%
TTM Avg
-298.11%
3Y Avg
-181.82%
5Y Avg
-125.27%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NextCure, Inc. (NXTC) | $20.16M | -351.86% | -230.83% | -130.66% | -58.18% |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.95M | -313.46% | -251.20% | -178.74% | -144.62% |
| Actuate Therapeutics Inc (ACTU)vs › | $19.14M | -2067.81% | -13234.78% | -6645.16% | -6645.16% |
| P3 Health Partners Inc. (PIII)vs › | $18.80M | -136.36% | -41.80% | -1184.66% | -795.29% |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.81M | -75.34% | -0.67% | -77.39% | -61.36% |
| Modular Medical, Inc. (MODD)vs › | $21.93M | -260.37% | -164.08% | -188.26% | -64.22% |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.22M | -40.40% | -55.95% | -53.10% | -83.38% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $17.99M | N/A | -3014.83% | -1589.49% | -1032.64% |
| LeonaBio, Inc. (LONA)vs › | $22.36M | -421.06% | -298.11% | -181.82% | -125.27% |
| PAVmed Inc. (PAVM)vs › | $17.74M | -34.50% | -796.82% | -138.82% | -407.45% |
ROE
-351.9%
ROA
-189.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -351.86% |
| 2026-03-31 | -204.61% |
| 2025-12-31 | -159.81% |
| 2025-09-30 | -245.33% |
| 2025-06-30 | -192.53% |
| 2025-03-31 | -88.66% |
| 2024-12-31 | -85.00% |
| 2024-09-30 | -77.41% |
| 2024-06-30 | -71.72% |
| 2024-03-31 | -64.35% |
| 2023-12-31 | -54.82% |
| 2023-09-30 | -51.84% |
| 2023-06-30 | -50.69% |
| 2023-03-31 | -45.54% |
| 2022-12-31 | -44.61% |
| 2022-09-30 | -40.97% |
| 2022-06-30 | -37.03% |
| 2022-03-31 | -34.34% |
| 2021-12-31 | -29.73% |
| 2021-09-30 | -27.36% |
| 2021-06-30 | -25.17% |
| 2021-03-31 | -22.52% |
| 2020-12-31 | -12.46% |
| 2020-09-30 | -10.43% |
| 2020-06-30 | -7.50% |
| 2020-03-31 | -5.38% |
| 2019-12-31 | -10.49% |
| 2019-09-30 | -17.39% |
| 2019-06-30 | -15.09% |
